Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
135
resultados
Última actualización
09/10/2025 [12:59:00]
Resultados 25 a 50 de 135
Resumen de: US2025298032A1
The present disclosure provides antibodies against chemokines, in particular to auto-antibodies against chemokines, nucleic acids encoding such antibodies and compositions comprising such antibodies. The present disclosure also provides a method for identifying (auto-)antibodies against chemokines, antibodies identified by said method and to the use of antibodies against chemokines as biomarkers, and for the treatment and diagnosis of diseases, such as COVID-19.
Resumen de: US2025297277A1
Provided herein are SARS-CoV-2 virus-like particles as well as methods and compositions for generating SARS-CoV-2 virus-like particles. The SARS-CoV-2 virus-like particles can load and deliver transcripts (including engineered transcripts that can include therapeutic agents) into cells expressing SARS-CoV-2 entry factors. The SARS-CoV-2 virus-like particles are also useful for detecting immune response in antibodies from subjects.
Resumen de: US2025297331A1
Methods are provided for detecting the presence of a specific genomic variant in a multiplex assay and distinguishing it from other genomic variants by interrogating one or more genomic loci specific to a particular genomic variant, and one or more semi-specific genomic loci present in in at least two genomic variants. The methods are useful for detecting a SARS-CoV-2 variant in a sample.
Resumen de: US2025295756A1
It is provided a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein 7, non-structural protein 8, non-structural protein 9, non-structural protein 10, non-structural protein 11, non-structural protein 12, an endoribonuclease, and a 2′-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome.
Resumen de: US2025295757A1
The invention relates to a polynucleotide encoding an attenuated SARS-CoV-2 or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons. The polynucleotide may comprise further modifications and may be comprised in an attenuated SARS-CoV-2. The invention further relates to methods for production of the polynucleotide and pharmaceutical products, e.g. for medical use.
Resumen de: WO2025198176A1
The present invention relates to a method for analyzing a molecule-molecule interaction and a device for detecting substances that interfere with such interactions. For example, the present invention relates to a method for analyzing protein-protein interactions, more specifically the interaction between the spike protein of SARS-CoV-2 and its receptor, human ACE2 protein, and a device capable of detecting neutralizing antibodies generated by vaccination on the basis of the analysis.
Resumen de: ZA202403414B
The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.
Resumen de: US2025297244A1
Compositions and methods for the diagnosis and treatment of severe Covid 19 and other inflammatory autoimmune disorders are disclosed.
Resumen de: US2025296936A1
The present disclosure relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Resumen de: US2025295759A1
The invention relates to a method of enhancing immunity, mRNA-based vaccines for SARS-COV-2 have demonstrated the enormous potential of mRNA therapeutics for safe and effective use in the general population. However, more recent studies have demonstrated decreasing vaccine effectiveness in terms of asymptomatic infection as well as symptomatic and severe infections starting around 4 months post second dose with mRNA-lipid nanoparticles (LNP) based regimens.
Resumen de: US2025295754A1
A method involving collecting viral particles from exhaled breath for developing oral vaccines against diseases like COVID-19. Infected individuals exhale breath into sterile equipment to separate viral particles through centrifuging and filtering, excluding saliva and other pathogens. The process avoids heat or methods that could destroy the viruses, ensuring the aerosol's vitality. Purified extracts, suspended in cold saline or water, undergo optional screening for contaminants and multiplication in sterile conditions. The final product is a quantified, purified aerosol extract of the virus, used for oral vaccine development.
Resumen de: US2025295657A1
Provided herein are methods of treating a patient, such as a human patient, having inflammation or an inflammatory disease or a disease in which inflammation is present, such as cardiovascular or vascular endothelium inflammation, such as pulmonary hypertension, restenosis, essential hypertension, atherosclerosis, stroke, sepsis, or a viral infection, such as a coronavirus infection, SARS-CoV-2. The methods comprise administering to the patient an amount of a compound as described herein effective to treat the patient. NCOA7-activating compounds and compositions also are provided. Also provided is a gene editing method of reducing inflammation or an inflammatory condition in a patient having a C at SNP rs 11154337, comprising editing the C to a G.
Resumen de: US2025295528A1
Disclosed herein are protective apparatuses, and associated systems, for minimizing the risk of transmission of SARS-CoV-2 and/or other infectious diseases between individuals in close proximity to one another including, for example, transmission through droplets projecting from the mouth or nasal region of an infected individual. Said apparatuses may comprise a substantially transparent shield component and a handle component comprising a connecting aspect. The protective apparatuses may comprise light emitting diodes and associated control means. The protective apparatuses of the present disclosure may further comprise a camera communicatively connected to a display screen.
Resumen de: US2025296985A1
The present invention relates to seven novel neutralizing human monoclonal antibodies (mAbs) THSC20.HVTR04, THSC20.HVTR06, THSC20.HVTR11, THSC20.HVTR26 THSC20.HVTR39, THSC20.HVTR55 and THSC20.HVTR88 and their nucleotide sequences isolated from a convalescent individual of Indian origin by antigen (RBD)-specific single B cell sorting and cloning of variable heavy and light IgG chain genes. The isolated mAbs demonstrate neutralization of wild type Wuhan strain and the following variants of concern: South African variant of concern (B.1.351), UK variant of concern (B.1.1.7), Brazilian variant of concern (PI), Delta (B.1.617.2) and Omicron (B.1.1.529) with exception of THSC20.HVTR39 unable to neutralize Gamma (P1). Of these THSC20.HVTR04 is able to potently neutralize Omicron BA.2 and BA.4/BA.5, THSC20.HVTR06 is able to neutralize Omicron BA.1, BA.2 and BA.5 with low potency, THSC20.HVTR11 potently neutralizes Omicron BA.1 and BA.2 and THSC20.HVTR26 neutralizes Omicron BA. 1 only with moderate potency. The present invention also discloses the binding affinity of the neutralizing mAbs to the receptor binding domain (RBD) representing Wuhan isolate (wild type). The present invention also, discloses the use of neutralizing monoclonal antibodies (mAbs) against SARS-CoV-2 for its diagnostic, prognostic, preventive and therapeutic purposes.
Resumen de: US2025296962A1
The present invention discloses an S-RBD trimer protein for a novel coronavirus. The trimer protein is composed of amino acid fragments at positions 319-537 in an RBD domain of an S protein of the novel coronavirus n a trimer form. A body is immunized with a vaccine prepared in the present invention taking the S-RBD trimer protein as an antigen and supplemented by an adjuvant, and then a hic neutralizing antibody for the novel coronavirus may be produced and may be used for treating and/or preventing novel coronavirus (SARS-CoV-2) infection and/or a novel coronavirus disease.
Resumen de: WO2024105235A1
The disclosure relates to a pharmaceutical composition comprising human plasma-derived polyclonal, anti-SARS-CoV-2 hyperimmune globulins and to said pharmaceutical composition for use in the treatment of a SARS-CoV-2 Omicron variant infection. The disclosure also relates to a method for the preparation of a polyclonal, hyperimmune globulin composition anti-SARS-CoV-2.
Resumen de: US12422397B1
The present invention generally includes methods, devices and/or kits for the detection of a COVID-19 infection in an individual by measuring the level or concentration or one or more ions present in a urine sample that is substantially free of COVID-19 RNA, antibodies, or antigen material.
Resumen de: US2025288542A1
Provided herein is a method for one or mor of preventing, treating, reducing the severity of acute respiratory distress syndrome (ARDS) in a subject at risk for contracting ARDS and infected with a coronavirus or SARS-CoV-2, comprising administering to the subject metformin, an analog or a derivative thereof, thereby preventing, treating, or reducing the severity of ARDS in the subject.
Resumen de: US2025290165A1
The invention provides compositions and methods allowing for rapid detection of SARS-CoV-2 variants.
Resumen de: US2025289826A1
Disclosed in the present invention are a PLpro protease inhibitor, and a preparation method and application thereof. The PLpro protease inhibitor can be combined with one or more pharmaceutically acceptable auxiliary materials or one or more other active ingredients to serve as a PLpro inhibitor to treat diseases caused by or diseases related to virus infection. The auxiliary material can be a carrier, a diluent, an adhesive, a lubricant, a wetting agent, etc. The protease inhibitor has high inhibitory activity, and can be used for broad-spectrum antivirals, especially for coronaviruses, for example, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU, SARS-CoV, MERS-CoV, SARS-CoV-2, etc., in particular SARS-CoV, MERS-CoV, SARS-CoV-2.
Resumen de: WO2025189658A1
The present invention relates to a recombinant protein vaccine for preventing and treating SARS-CoV-2 variants JN.1, BA.2.86, and XBB lineages, a drug for combined use, and use. To solve the problem that Omicron JN.1, BA.2.86, and XBB lineage subvariants exhibit significant immune escape and blotting immunity after previous vaccination and viral infection, an XBB.1.5 recombinant protein vaccine is provided. The vaccine, when administered either intramuscularly or intranasally, induces strong humoral, cellular, and mucosal immune responses against JN.1, BA.2.86, and XBB lineage variants. Compared with homologous vaccination, after inactivated or mRNA vaccines are applied, the vaccine is used for heterologous vaccination to obtain a better immune response. Moreover, the vaccine induces effective protective immunity in vivo against Omicron EG.5.1 live virus attacks. Thus, the XBB.1.5 vaccine has clinical efficacy.
Resumen de: WO2025189415A1
The present invention relates to a recombinant protein vaccine for preventing and treating SARS-CoV-2 variant JN.1, BA.2.86, and XBB lineages, a combination drug, and a use. To address significant immune escape and immune imprinting phenomena observed with Omicron JN.1, BA.2.86 and XBB lineage subvariants following prior vaccination or virus infection, an XBB.1.5 recombinant protein vaccine is provided. This vaccine elicits potent humoral and cellular immune responses against currently circulating JN.1, BA.2.86, and XBB lineage variants. Compared with homologous vaccination, heterologous vaccination with this vaccine following administration of an inactivated or mRNA-based vaccine achieves superior immune responses. Moreover, the vaccine induces effective protective immunity against live Omicron EG.5.1 virus attack in vivo. Therefore, the monovalent XBB.1.5 vaccine has clinical use value.
Resumen de: US2025288547A1
Up-regulation of caspase has been found in COVID-19 patients, and also occurs in patients suffering from diabetes, hypertension, metabolic syndrome, and other conditions. Such up-regulation can be responsible for poor clinical outcomes in patients having such diseases or disorders, as such up-regulation leads to a process called pyroptosis: death and malfunction of immune system cells, particularly of certain types of lymphocytes. An inhibitor of caspase such as a caspase 1 inhibitor, or “pan-caspase” inhibitor (i.e., an inhibitor of multiple caspase types including caspase-1), can be used to treat COVID-19 patients or individuals at risk of infection, by limiting the malfunction of the immune system. A caspase-1 or pan-caspase inhibitor is advantageously administered before or very early in the course of infection by a positive-sense, single-stranded RNA virus such as SARS-COV, MERS-COV, or SARS-Cov-2.
Resumen de: US2025289871A1
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.
Nº publicación: WO2025192852A1 18/09/2025
Solicitante:
AGENCY DEFENSE DEV [KR]
\uAD6D\uBC29\uACFC\uD559\uC5F0\uAD6C\uC18C
Resumen de: WO2025192852A1
The present invention relates to an antibody mRNA for treating SARS-coronavirus-2 delta infection and a composition including same, the composition exhibiting excellent therapeutic efficacy against SARS-coronavirus-2 delta infection.
BOPI
Sede Electrónica
